Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Lymphoma: early-phase trial registry
5 of 40 indexed Refractory Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #368 of 28,707 conditions by registered trial count.
40 US clinical trials · 5 currently recruiting · #368 of 28,707 conditions by registered trial count
Refractory Lymphoma: 40 US clinical trials tracked, 5 recruiting.
Refractory Lymphoma is the subject of 40 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 39 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 33 of these trials.
Enrollment posture brief
Registry condition refractory-lymphoma
OPEN 5 | RECR 13% | LATE 0 | EARLY 39 | RANK #368 | SPON 33
Volume-matched condition peers
Nearest open-share peer: Acute Respiratory Infection (13% recruiting · 8 trials)
Refractory Lymphoma lists 5 open slots (13% of 40 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Lymphoma is recruiting below its size-band peers.
5 of 40 indexed trials (12.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Refractory Lymphoma research.
National Cancer Institute (NCI) accounts for 33 of 40 trials (82.5%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 35 among the 40 trials that report a genuine target (sentinel values excluded). 40 of those (100%) plan for fewer than 100 participants.
-
Refractory Lymphoma research is mostly interventional.
40 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
40 total, page 1 of 1
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
NCT03418038
Avo In R/R And Previously Untreated MCL
Austin I Kim
NCT04855695
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
NCT04870944
Epco, Zanu, Ritux for R/R FL or MZL
Reid Merryman, MD
NCT06563596
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Paolo Caimi, MD
NCT06916767
Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)
National Cancer Institute (NCI)
NCT04439175
Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)
National Cancer Institute (NCI)
NCT04439344
Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)
National Cancer Institute (NCI)
NCT04439318
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)
National Cancer Institute (NCI)
NCT06390865
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)
National Cancer Institute (NCI)
NCT06357975
Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)
National Cancer Institute (NCI)
NCT06390839
Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)
National Cancer Institute (NCI)
NCT04439136
Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)
National Cancer Institute (NCI)
NCT04439201
Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)
National Cancer Institute (NCI)
NCT04439110
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)
National Cancer Institute (NCI)
NCT06400238
Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)
National Cancer Institute (NCI)
NCT06390852
Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)
National Cancer Institute (NCI)
NCT04439227
Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)
National Cancer Institute (NCI)
NCT04439331
Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)
National Cancer Institute (NCI)
NCT06357988
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)
National Cancer Institute (NCI)
NCT04439188
Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)
National Cancer Institute (NCI)
NCT04439279
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)
National Cancer Institute (NCI)
NCT05490771
Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)
National Cancer Institute (NCI)
NCT06308822
Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)
National Cancer Institute (NCI)
NCT04439123
Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)
National Cancer Institute (NCI)
NCT06385496
Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)
National Cancer Institute (NCI)
NCT06400225
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
NCT04439292
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)
National Cancer Institute (NCI)
NCT06400251
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT05071209
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
National Cancer Institute (NCI)
NCT04439149
Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)
National Cancer Institute (NCI)
NCT06360575
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)
National Cancer Institute (NCI)
NCT06385483
Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)
National Cancer Institute (NCI)
NCT06303167
Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)
National Cancer Institute (NCI)
NCT06390826
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
National Cancer Institute (NCI)
NCT04439266
Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)
National Cancer Institute (NCI)
NCT04439253
Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)
National Cancer Institute (NCI)
NCT04439357
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Children's Oncology Group
NCT02323880
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
NCT02780804
Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)
Massachusetts General Hospital
NCT06004167
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
| Phase 2 | 33 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Lymphoma page
40 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 5 Refractory Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Refractory Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Lymphoma condition card totals 40 registered trials; most-linked intervention Biopsy Procedure; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.